All AbMole products are for research use only, cannot be used for human consumption.
In vitro: Beyond ALK, IGF1R, and InsR, Brigatinib (AP26113) also potently inhibits FLT3 and ROS1 with IC50 values of 2.1 and 1.9 nM, respectively. It does not show significant activity toward c-Met or Ron up to 1 μM. Brigatinib (AP26113) overcomes the resistance of EGFR-triple-mutant and the activity depends on ATP-competitive manner with less affection to wild-type EGFR.
In vivo: Mouse PK parameters for Brigatinib (AP26113) following oral dosing (10 mg/kg): Cmax=448 ng/mL,t1/2=5.8 h. And in CD rats, after dosing at 3 mg/kg i.v, CL=0.46 L/(h·kg), t1/2=4.8 h, Vss=7.8 L/kg; Dosed at 10 mg/kg p.o, Cmax=305 ng/mL, tmax=4 h, t1/2=3.4 h， F%=52. Brigatinib (AP26113) demonstrates dose-dependent antitumor activity. Brigatinib (AP26113) demonstrates growth inhibition activity in PC9 triple-mutant xenograft model and in combination with anti-EGFR antibody to potentiate the efficacy both in vitro and in vivo as shown in first-generation EGFR-TKI-resistant patients.
Mol Cancer Ther. 2022 Jul 5;21(7):1060-1066.
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
AP26113 (Brigatinib) purchased from AbMole
 |
Source | Mol Cancer Res (2015). Figure 1. AP26113 |
| Method | Western blot | |
| Cell Lines | KARPAS-299, SUP-M2 cell lines | |
| Concentrations | 0, 100, 300, and 1000 nmol/L | |
| Incubation Time | 20 nmol/L | |
| Results | In all AP26113-resistant KARPAS-derived cell lines, STAT-3 P-Tyr705 was present at higher drug doses than the one observed for parental cells and correlated with the persistent NPM-ALK phosphorylation |
| Cell Experiment | |
|---|---|
| Cell lines | H3122, H3122 CR, A549, H1299, SKBR3, H522, H460, and BT474 cells |
| Preparation method | Survival assays For 72-h drug treatments, 3000 cells were plated in replicates of six into 96-well plates. Following drug treatments, cells were incubated with CellTiter-Glo assay reagent (Promega) for 10 min and luminescence was measured using a Centro LB 960 microplate luminometer (Berthold Technologies). |
| Concentrations | 0~1µ M |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | H3122 CR xenografts in athymic nude mice |
| Formulation | saline |
| Dosages | 50 mg/kg/day for 17 days |
| Administration | oral gavage |
| Molecular Weight | 584.09 |
| Formula | C29H39ClN7O2P |
| CAS Number | 1197953-54-0 |
| Solubility (25°C) | Ethanol 6 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related ALK Products |
|---|
| F-1
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50 values of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. |
| TL13-22
TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM. |
| TL13-110
TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM. |
| ALK inhibitor 2
ALK inhibitor 2 is a potent pyrimidin ALK inhibitor. |
| NVL-655 TFA
NVL-655 (ALK-IN-27) TFA is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 (ALK-IN-27) TFA has an IC50 of 2.7 nM. It can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
